ACADIA Pharmaceuticals Inc. (ACAD)

13.03
NASDAQ : Health Technology
Prev Close 13.30
Day Low/High 12.86 / 13.30
52 Wk Low/High 12.77 / 41.20
Avg Volume 2.93M
Exchange NASDAQ
Shares Outstanding 125.01M
Market Cap 1.66B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Acadia Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acadia Pharmaceuticals, Inc.

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals And Neuren Pharmaceuticals Announce Exclusive License Agreement For The North American Development And Commercialization Of Trofinetide In Rett Syndrome

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome...

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

ACAD ALERT NOTICE: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.; Investor Deadline - ACAD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

Investor Alert: Kaplan Fox Announces Investigation Of ACADIA Pharmaceuticals

Investor Alert: Kaplan Fox Announces Investigation Of ACADIA Pharmaceuticals

NEW YORK, Aug. 1, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 8, 2018

ACADIA Pharmaceuticals To Announce Second Quarter 2018 Financial Results On August 8, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

ACADIA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

NEW ORLEANS, July 27, 2018 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

KASKELA LAW LLC: Shareholder Class Action Lawsuit Filed Against ACADIA Pharmaceuticals Inc.

Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

RM LAW Announces Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

RM LAW Announces Class Action Lawsuit Against ACADIA Pharmaceuticals Inc.

BERWYN, Pa., July 26, 2018 /PRNewswire/ --  RM LAW, P.

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against ACADIA Pharmaceuticals Inc. - ACAD

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against ACADIA Pharmaceuticals Inc. - ACAD

RADNOR, Pa., July 26, 2018 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Acadia Pharmaceuticals, Inc.

Federman & Sherwood announces that on July 19, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of California against Acadia Pharmaceuticals, Inc.

New Securities Class Action Filed Against ACADIA Pharmaceuticals, Inc. (ACAD); Block & Leviton Encourages ACADIA Investors To Contact The Firm

New Securities Class Action Filed Against ACADIA Pharmaceuticals, Inc. (ACAD); Block & Leviton Encourages ACADIA Investors To Contact The Firm

BOSTON, July 24, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) And Lead Plaintiff Deadline - September 17, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) And Lead Plaintiff Deadline - September 17, 2018

NEW YORK, July 24, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACADIA Pharmaceuticals Inc.

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

Austin D. Kim, Executive Vice President, General Counsel And Secretary (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of ACADIA Pharmaceuticals Inc. (ACAD)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of ACADIA Pharmaceuticals Inc. (ACAD)

NEW YORK, July 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals, Inc. (ACAD) Investigated By Block & Leviton LLP For Violations Of Federal Securities Laws

ACADIA Pharmaceuticals, Inc. (ACAD) Investigated By Block & Leviton LLP For Violations Of Federal Securities Laws

BOSTON, July 18, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ACADIA Pharmaceuticals Inc. - ACAD

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc.

Hagens Berman Alerts Investors In ACADIA Pharmaceuticals Inc. (ACAD) To The Firm's Investigation Of Possible Disclosure Violations

Hagens Berman Alerts Investors In ACADIA Pharmaceuticals Inc. (ACAD) To The Firm's Investigation Of Possible Disclosure Violations

SAN FRANCISCO, July 11, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in ACADIA Pharmaceuticals Inc.

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

August 24th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading today, for the August 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new August 24th contracts and identified one put and one call contract of particular interest.

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with...

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

First Week Of July 20th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D- (Sell)